Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Simone, Stensgaard"'
Publikováno v:
Cancer Treatment and Research Communications, Vol 39, Iss , Pp 100802- (2024)
Background: Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This could improve consolidation therapy of progressing patients. However, the
Externí odkaz:
https://doaj.org/article/3df6c84844b845c8b2c5af5bcd5540bc
Autor:
Inger Johanne Zwicky Eide, Simone Stensgaard, Åslaug Helland, Simon Ekman, Anders Mellemgaard, Karin Holmskov Hansen, Saulius Cicenas, Jussi Koivunen, Bjørn Henning Grønberg, Boe Sandahl Sørensen, Odd Terje Brustugun
Publikováno v:
Eide, I J Z, Stensgaard, S, Helland, Å, Ekman, S, Mellemgaard, A, Hansen, K H, Cicenas, S, Koivunen, J, Grønberg, B H, Sørensen, B S & Brustugun, O T 2022, ' Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations : a post-hoc subgroup analysis with pooled data from two phase II clinical trials ', Translational Lung Cancer Research, vol. 11, no. 6, pp. 953-963 . https://doi.org/10.21037/tlcr-21-995
Translational Lung Cancer Research (TLCR)
Translational Lung Cancer Research (TLCR)
Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 is largely unknown. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf92d28602e537f5a1f22275cc40a2cd
https://pure.au.dk/portal/da/publications/osimertinib-in-nonsmall-cell-lung-cancer-with-uncommon-egfrmutations(f24c391e-f99d-4b57-abe6-9af9f1018ea3).html
https://pure.au.dk/portal/da/publications/osimertinib-in-nonsmall-cell-lung-cancer-with-uncommon-egfrmutations(f24c391e-f99d-4b57-abe6-9af9f1018ea3).html
Autor:
Simone Stensgaard, Astrid Thomsen, Julie G. Dissing, Sofie Helstrup, Peter Meldgaard, Boe S. Sorensen
Publikováno v:
Cancer Research. 83:969-969
Introduction: Immunotherapy has altered the therapeutic landscape for patients with advanced non-small cell lung cancer (NSCLC). The immune checkpoint inhibitor pembrolizumab targets the PD-1 signaling axis and has produced durable clinical response,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d2f4a5cc95ea9e771cce883edd4b232
https://doi.org/10.1158/1538-7445.am2023-969
https://doi.org/10.1158/1538-7445.am2023-969
Autor:
Inger Johanne Zwicky, Eide, Simone, Stensgaard, Åslaug, Helland, Simon, Ekman, Anders, Mellemgaard, Karin Holmskov, Hansen, Saulius, Cicenas, Jussi, Koivunen, Bjørn Henning, Grønberg, Boe Sandahl, Sørensen, Odd Terje, Brustugun
Publikováno v:
Translational lung cancer research. 11(6)
Osimertinib is standard of care forWe identified patients with uncommonOf 299 enrolled patients in the two trials, 21 patients with uncommon mutations were identified; 12 patients had a single mutation (G719X or L861Q), one patient had L861Q and an e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bbd0f24101628cf538fd982611fac652
https://pubmed.ncbi.nlm.nih.gov/35958324
https://pubmed.ncbi.nlm.nih.gov/35958324